A closer look at vancomycin, teicoplanin, and antimicrobial resistance

Journal of Chemotherapy

Volumn 9, Issue 5, 1997, Pages 311-335

  Zeckel, M L ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Glycopeptides; Resistance; Staphylococcus aureus; Teicoplanin; Vancomycin

Indexed keywords

CLOXACILLIN; GENTAMICIN; GLYCOPEPTIDE; TEICOPLANIN; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; BACTERIAL ENDOCARDITIS; BACTERIAL INFECTION; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; GRAM POSITIVE BACTERIUM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NEUTROPENIA; REVIEW; STAPHYLOCOCCUS AUREUS; THROMBOCYTOPENIA;

EID: 0030774156     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1997.9.5.311     Document Type: Review

References (223)

1. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995 Aug 23-30; 274(8): 639-44.
2. Voiriot P. Infections a Staphylocoque resistants a la methicilline. Ann Med 1989;28:567-572.
3. Maple PAC, Hamilton-Miller JMT, Brumfitt W. Worldwide antibiotic resistance in methicillin-resistant Staphylococcus aureus. Lancet 1989;537-539.
4. Aspock C, Koller W, Rotter M. Resistenzverhalten von Staphylokokken am Allgemeinen Krankenhous der Stadt Wien (Juli bis Dezember 1991). Wien Klin Wochenschr 1994;106:20-26.
5. Venditti M, Baiocchi P, Brandimarte C. Oxacillin-resistant Staphylococcus aureus isolates in an Italian university hospital. J Chemother 1994;6:25-28.
6. Mehtar-S. The continuing problem of 'hospital staphylococci': why? J Chemother 1994;6 (Suppl 4):25-31.
7. Marton A, Gulyas M, Munoz R, Tomasz A. Extremely high incidence of antibiotic resistance in clinical isolates of Streptococcus pneumoniae in Hungary. J Infect Dis 1991;163:542-548.
8. Spencer RC, Goering R. A critical review of the in-vitro activity of teicoplanin. Int J Antimicrob Agents 1995;5:169-177.
9. Brogden RN, Peters DH. Teicoplanin: a reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994;47:823-854.
10. Campoli-Richards D, Brogden RN, Faulds D. Teicoplanin. a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1990;40:449-486.
11. Goldstein FW, Coutrot A, Seiffer A, Acar JF. Percentages and distributions of teicoplanin- and vancomycin- resistant strains among coagulase-negative staphylococci. Antimicrob Agents Chemother 1990;34(5):899-900.
12. Maugein J, Pellegrin JL, Brassard G, Fourche J, Leng B, Reiffers J. In vitro activities of vancomycin and teicoplanin against coagulase-negative staphylococci isolated from neutropenic patients. Antimicrob Agents Chemother 1990;35(5):901-903.
13. Low DE, McGeer A, Poon R, Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations. Antimicrob Agents Chemother 1989;33:585-588.
14. Moore EP, Speller DC. In-vitro teicoplanin-resistance in coagulase-negative staphylococci from patients with endocarditis and from a cardiac surgery unit. J Antimicrob Chemother 1988;21:417-424.
15. Vedel G, Leruez M, Lemann F, Hraoui E, Ratovohery D. Prevalence of Staphylococcus aureus and coagulase-negative staphylococci with decreased sensitivity to glycopeptides as assessed by determination of MICs. Eur J Clin Microbiol Infect Dis 1990;9:820-822.
16. Goldstein FW, Geslin P, Acar JF, and the French Study Group. Comparative activity of teicoplanin and vancomycin against 400 penicillin susceptible and resistant Streptococcus pneumoniae. Eur J Clin Microbiol Intect Dis 1994;13:33-34.
17. Lindholm DD, Murray JS. Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis. N Engl J Med 1966;274:1047-1051.
18. Krogstad DJ, Moellering RC, Greenblatt DJ. Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol 1980;20:197-201.
19. Albrecht LM, Rybak MJ, Warbasse LH, Edwards DJ. Vancomycin protein binding in patients with infections caused by Staphylococcus aureus. Ann Pharmacother 1990;25:713-715.
20. Tan CC, Lee HS, Ti TY, Lee EJC. Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure. Ther Drug Monit 1990;12:29-34.
21. Morita K, Yamaji A. Changes in serum protein binding of vancomycin in patients with methicillin-resistant Staphylococcus aureus infection: The role of serum α1-acid glycoprotein levels. Ther Drug Monit 1995;17:107-112.
22. Ackerman BH, Taylor EH, Olsen KM, et al. Vancomycin serum protein binding determined by ultrafiltration. Drug Intell Clin Pharm 1988; 22:300-303.
23. Wittendorf RW, Swagzdis JE, Gifford R, et al. Protein binding of glycopeptide antibiotics with diverse physical-chemical properties in mouse, rat, and human serum. J Pharmacokinet Biopharm 1987; 15:5-13.
24. Cantu TG, Dick JD, Elliott DE, Humphrey RL, et al. Protein binding of vancomycin in a patient with immunoglobulin A myeloma. Antimicrob Agents Chemother 1990; 34:1459-1461.
25. Garrison MW, Vance-Bryan K, Larson TA, Toscano JP, Rotschafer IC. Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrob Agents Chemother 1990;34:1925-31.
26. Stanley D, McGrath BJ, Lamp KC, Rybak MJ. Effect of human serum on killing activity of vancomycin and teicoplanin against Staphylococcus aureus. Pharmacotherapy 1994 Jan-Feb;14(1):35-9.
27. Bernareggi A, Borgonovi M, Del Favero A, Rosina R, Gavanaghi L. Teieoplanin binding in plasma following administration of increasing doses to healthy volunteers. Eur J Drug Metab Pharmacokinet 1991;3:256-260.
28. Dykhuizen RS, Harvey G, Stephenson N, Nathwani D, Gould IM. Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob Agents Chemother 1995;39:1842-1847..
29. Bauernfeind A. Bactericidal activity of antibiotics alone and in combination against Enterococcus faecalis in a pharmacodynamic model. Clin Infect Dis 1992;15:481-485.
30. Lamp KC, Rybak MJ, Bailey EM, Kaatz GW. In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob Agents Chemother 1992; 36:2709-2714.
31. Bailey EM, Rybak MJ, Kaatz GW. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob Agents Chemother 1991; 35:1089-1092.
32. Kennedy HF, Seal DV. Influence of inoculum, medium and serum on the in-vitro susceptibility of coagulase-negative staphylococci to teicoplanin and vancomycin. J Antimicrob Chemother 1996;37:1103-1109.
33. Chambers HF, Kennedy S. Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob Agents Chemother 1990; 34:510-514.
34. Traub WH, Spohr M, Bauer D. Teicoplanin combined with various antibiotics and human blood against a multiple-drug-resistant strain of Staphylococcus aureus. Chemotherapy 1991;37(3):186-95.
35. Arrieta AC, Stutman HR, Akaniro JC, Vargus OM. In vitro activity of teicoplanin compared with vancomycin against methicillin-resistant Staphylococcus aureus derived from cystic fibrosis sputum. Diagn Microbiol Infect Dis 1992;15:247-251.
36. Greenberg RN, Benes CA. Time-kill studies with oxacillin, vancomycin, and teicoplanin versus Staphylococcus aureus. J Infect Dis 1990;161;1036-1037.
37. Peetermans WL, Hoogeterp JJ, Hazekamp-van-Dokkum AM, van-den-Broek P, Mattie H. Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. Antimicrob Agents Chemother 1990;34:1869-74.
38. Cohen R, Barre J, Varon L. A comparative microbiological and pharmacokinetic activity of vancomycin and teicoplanin (published erratum appears in Pathol Biol (Paris) 1992 Nov;40(9):894. Pathol Biol Paris. 1992 Oct; 40(8): 831-44.
39. McGrath BJ, Kang SL, Kaatz GW, Rybak MJ. Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis. Antimicrob Agents Chemother 1994;38: 2034-40.
40. Aldridge KE, Gelfand MS, Schiro DD, Barg NL. Therapid emergence of fluoroquinolone-methicillin-resistant Staphylococcus aureus infections in a community hospital. An in vitro look at alternative antimicrobial agents. Diagn Microbiol Infect Dis 1992;15:601-8.
41. Aldridge KE, Janney A, Sanders CV. Comparison of the activities of coumermycin, ciprofloxacin, teicoplanin, and other non-beta-lactam antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus from various geographical locations. Antimicrob Agents Chemother 1985;28:634-8.
42. Lentino JR, Strodthman R. Comparison of in vitro activity of daptomycin, vancomycin and fluoroquinolones in broth and serum against Staphylococcus epidermidis as determined by time-kill kinetics. Chemotherapy 1989;35:168-73.
43. Pallanza R, Scotti R, Arioli V. Bactericidal activity of teicoplanin in an in-vitro two-compartment kinetic model. J Antimicrob Chemother 1988;21 (Suppl A):15-21.
44. Doit CP, Bonacorsi SP, Fremaux AJ. In vitro killing activities of antibiotics at clinically achievable concentrations in cerebrospinal fluid against penicillin-resistant Streptococcus pneumoniae isolated from children with meningitis. Antimicrob Agents Chemother 1994;38:2655-9.
45. Felmingham D, Foxall P, O'Hare M, Gruneberg R. The bactericidal activity of vancomycin and teicoplanin against Streptococcus pneumoniae. Scand J Infect Dis 1990;72(Suppl):20-5.
46. Wiland AM, Plaisance KI, Schwalbe RS. In vitro evaluation of high-level, gentamicin-resistant enterococci isolated from bacteremic patients. Pharmacotherapy 1994;14:89-94.
47. Traub WH, Leonhard B, Bauer D. Enterococcus faecium: in vitro activity of antimicrobial drugs, singly and combined, with and without defibrinated human blood, against multiple-antibiotic-resistant strains. Chemotherapy 1993;39:254-64.
48. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990; 34 (6):1227-1231.
49. Ishii T, Takayama Y, Takase Y, Orikasa Y. Antibacteriological activities of arbekacin and vancomycin against strains of MRSA. Jpn J Antibiot 1994;47:647-54.
50. Thabaut A, Meyran M. Comparative bactericidal activity of fourteen antibiotics against Staphylococcus aureus. Pathol Biol (Paris) 1989;37:321-8.
51. Maple PA, Hamilton-Miller JM, Brumfitt W. Differing activities of quinolones against ciprofloxacin-susceptible and ciprofloxacin-resistant, methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1991;35:345-50.
52. Lagast H, Dodion P, Klastersky J. Comparison of pharmacokinetics and bactericidal activity of teicoplanin and vancomycin. J Antimicrob Chemother 1986;18:513-20.
53. Watanakunakorn C. In-vitro selection of resistance of Staphylococcus aureus to teicoplanin and vancomycin. J Antimicrob Chemother 1990;25:69-72.
54. Serazin V, Mougeot C, Libert IM. Methicillin-resistant Staphylococcus aureus and glycopeptides: in vitro selection of resistance. Path Biol 1994;42:323-327.
55. Shlaes DM, Shlaes JH, Vincent S, et al. Teicoplanin-resistant Staphylococcus aureus expresses a novel membrane protein and increases expression of penicillin-binding protein 2 complex. Antimicrob Agents Chemother 1993;37:2432-2437.
56. Kaatz GW, Seo SM, Dorman NJ, Lerner SA. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J Infect Dis 1990;162:103-108.
57. Scheel O, Lyon DJ, Cheng AFB. In-vitro susceptibility of isolates of methicillin-resistant Staphylococcus aureus 1988-1993. J Antimicrob Chemother 1996;37:243-251.
58. Baiocchi P, Capone A, Vendetti M. Changes in susceptibilities to teicoplanin, vancomycin and other antibiotics among Staphylococcus aureus isolates in a tertiary-care university hospital. Int J Antimicrob Agents 1996;7:93-96.
59. Shlaes DM, Shlaes JH. Teicoplanin selects for Staphylococcus aureus that is resistant to vancomycin. Clin Infect Dis 1993;20:1071-1072.
60. Centers for Disease Control and Prevention. Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996. Morb Mort Wkly Rep 1997;46:624-6.
61. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-136.
62. Centers for Disease Control and Prevention. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States. Morb Mort Wkly Rep 1997;46:813-814.
63. Noble WC Virani Z Cree RG. Co-transfer of vancomycin and other resistance penes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;72:195-8.
64. Daum RS, Gupta S, Sabbagh R, Milewski WM. Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility. J Infect Dis 1992;166:1066-1072.
65. Sieradzki K, Tomasz A. Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. J Bacteriol 1997;179:2557-66.
66. Eloy C, Lagel R, Croix JC. Clinical failure of teicoplanin in a patient with nosocomial methicillin-resistant Staphylococcus aureus lower respiratory infection. Sem Hop Paris 1991;67:1427-1428.
67. Goering RW, Fey PD, Goldstein FW. Usefulness of pulse-field gel electrophoresis in the epidemiological analysis of Staphylococcus aureus isolates with decreased susceptibility to teicoplanin. Eur J Clin Microbiol Infect Dis 1995;14(Suppl1):3-5.
68. Brunet F, Vedel G, Dreyfus F, et al. Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin. Eur J Clin Microbiol Infect Dis 1990;9:145-147.
69. Manquat G, Croize J, Stahl JP Meyran M, Hirtz P, Micoud M. Failure of teicoplanin treatment associated with an increase in MIC during therapy of Staphylococcus aureus septicaemia. J Antimicrob Chemother 1992;29:731-732.
70. Cunney RJ, McNamara E, Al Ansari N, et al. Failure of teicoplanin therapy in Staphylococus aureus septicaemia. J Hosp Infect 1994;28:324-525.
71. Mainardi JL, Shlaes DM, Goering RV, Shlaes JH, Acar JF, Goldstein FW. Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus. J Infect Dis 1995;171:1646-1650.
72. Quincampoix JC, Carbonne A, Loyer D, et al. Follow-up of a nosocomial outbreak of methicillin-resistant strains of Staphylococcus aureus (MRSA) with decreased susceptibility to teicoplanin. Abstract C-167. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada. September 28, 1997.
73. Van Eldere J, Hoefnagels-Schuermans A, Peetermans WE, Van Lierde S, Verwaest C. Nosocomial transmission of a methicillin-resistant Staphylococcus aureus strain with reduced teicoplanin susceptibility. Abstract J-122. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada. September 28, 1997.
74. Rupp ME, Archer GL. Coagulase-negative staphylococci: Pathogens associated with medical progress. Clin Infect Dis 1994;19:231-245.
75. Kloos WE, Bannerman TL. Update on clinical significance of coagulase negative staphylococci. Clin Microbiol Rev 1994;7:117-140.
76. Spencer RC. Epidemiology of infection in ICUs. Intensive Care Med 1994;20 (Suppl 4):S2-6.
77. Gaynes RP, Edwards JR, Jarvis WR, et al. Nosocomial infections among neonates in high-risk nurseries in the United States. Pediatrics 1996;98:357-361.
78. Bhattacharyya N, Kosloske AM,. Macarthur C. Nosocomial infection in pediatric surgical patients: a study of 608 infants and children. J Ped Surg 1993;28:338-43.
79. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987;16:927-931.
80. Veach LA, Pfaller MA, Barren M, Koontz FP, Wenzel RP. Vancomycin resistance in Staphylococcus baemolyticus causing colonization and bloodstream infection. J Clin Microbiol 1990;28:2064-2068.
81. Sanyal D, Johnson AP, George RC, Cookson BD, Williams AJ. Peritonitis due to vancomycin-resistant Staphylococcus epidermidis (letter). Lancet 1990;337:54.
82. Schmitz FJ, Kitzrow M, Heinz HP. Antimicrobial susceptibility and typing of coagulase negative staphylococci from different intensive care units. Klin Labor 1996;42:403-410.
83. Cavallo JD, Talarmin A, Fabre R, et al. Susceptibility of nosocomial gram-positive cocci to teicoplanin and other antibiotics. Eur J Clin Microbiol 1995;14:923-924.
84. Desroys Du Rourc F, Herrmann JL, Lagrange PH, Bouvet A. Action of teicoplanin on coagulase negative staphylococci in hospital units of the hospital Hotel-Dieu in Paris. Pathol Biol 1993;41:302-6.
85. Cercenado E, Garcia-Leoni ME, Bouza E. Emergence of teicoplanin-resistant coagulase-negative staphylococci. J Clin Microbiol 1996;34:1765-1768.
86. Tripodi ME, Attanasio V, Adinolfi LE. Prevalence of antibiotic resistance among clinical isolates of methicillin-resistant staphylococci. Eur J Clin Microbiol Infect Dis 1994;13:148-52.
87. Schwalbe RS, Ritz WJ, Verma PR, Barranco EA, Gilligan PH. Selection for vancomycin resistance in clinical isolates of Staphylococcus haemolyticus. J Infect Dis 1990;161:45-51.
88. Biavasco F, Giovanetti E, Montanari MP, Lupidi R, Varaldo PE. Development of in-vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species. J Antimicrob Chcmother 1991;27:71-79.
89. Watanakunakorn C. In-vitro induction of resistance in coagulase-negative staphylococci to vancomycin and teicoplanin. J Antimicrob Chemother 1988;22:321-324.
90. Goessens WHF, Den Hollender JG, Lemmens-Den toom N, Mouton JW, Verbrugh HA. Selection of glycopeptide resistant coagulase negative staphylococci in an in-vitro pharmacokinetic model. Abstract C-163. In Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Canada. September 28, 1997.
91. Krcmery V Jr, Trupl J, Drgona L, Lacka J, Kukuckova E, Oravcova E. Nosocomial bacteremia due to vancomycin resistant Staphylococcus epidermidis in four patients with cancer, neutropenia, and previous treatment with vancomycin. Eur J Clin Microbiol Infect Dis 1996;15:259-61.
92. Chomarat M, Espinouse D, Flandrois J-P. Coagulase-negative staphylococci emerging during teicoplanin therapy and problems in the determination of their sensitivity. J Antimicrob Chemother 1991;27:475-480.
93. Espinouse D, Chomarat M. Evaluation of teicoplanin in neutropenic patients: advantages and limits. Path Biol 1990;38:552-556.
94. Jones RL. Coagulase-negative staphylococci emerging during teicoplanin therapy and the determination of their sensitivity. J Antimicrob Chcmother 1992;29:725-726.
95. Chomarat M, Espinouse D, Flandrois J-P. Reply: Coagulase-negative staphylococci emerging during teicoplanin therapy and the determination of their sensitivity. J Antimicrob Chemother 1992;29:726-727.
96. Jones RN, Erwin ME, Anderson SC. Emerging multiply resistant enterocci among clinical isolates. Diagn Microbiol Infect Dis 1995;21:95-100.
97. Anonymous. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HIPAC). Morb Mort Wkly Rep 1995;44:1-13.
98. Arthur M, Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 1993;37:1563-1571.
99. Gordon S, Swenson JM, Hill BC, et al. Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States. J Clin Microbiol 1992;30:2373-2378.
100. Centers for Disease Control and Prevention. Nosocomial enterococci resistant to vancomycin - United States, 1989 - 1993. Morb Mort Wkly Rep 1993;42:597-599.
101. Livornese LL, Dias S, Samel C, et al. Hospital-acquired infection with vancomycin-resistant Enterococcus faccium transmitted by electronic thermometers. Ann Intern Med 1992;117:112-116.
102. Kaplan AH, Gilligan PH, Facklam RR. Recovery of resistant enterococci during vancomyein prophylaxis. J Clin Microbiol 1988;26:1216-1218.
103. Karanfil LV, Murphy M, Josephson A, et al. A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol 1992;13:195-200.
104. Peetermans WL, Sebens FW, Guiot HFL. Vancomycin-resistant Enterococcus faecalis in a bone-marrow transplant recipient. Scand J Infect Dis 1991;23:105-109.
105. Arduino RC, Murray BE. Vancomycin resistance in Gram-positive organisms. Curr Opin Infect Dis 1993;6:715-724.
106. Venditti M, Fimiani C, Baiocchi P, et al. Infections by ampicillin-resistant Enterococci: a case control study. J Chemother 1994;6:121-126.
107. Zervos MF, Dembinski D, Mike-sell T, Schaberg D. High-level resistance to gentamicin in Streptococcus faecalis: risk factors and evidence for exogenous acquisition of infection. J Infect Dis 1986;153:1075-1083.
108. Fraimow HS, Jungkind DL. Vancomycin-dependent enterococci: a clinical and laboratory assessment. Adv Exp Med Biol 1995;390:97-107.
109. Green M, Shlaes JH, Barbadora K, Shlaes DM. Bacteremia clue to vancomycin-dependent Enterococcus faecium. Clin Infect Dis 1995;20(3):712-4.
110. Moellering RC, Gibbs M, Harding I. Successful treatment of vancomycin resistant enterococcal (VRE) infections with teicoplanin. Abstract 5309. In Abstracts of the 20th International Congress of Chemotherapy. Sydney, Australia, June 29, 1997.
111. Levine DP, Cushing RD, Jui J, Brown WJ. Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center. Ann Intern Med 1982;92:330-338.
112. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Int Med 1991;119:674-680.
113. Sorrell TC, Packham DR, Shanker S, Foldes M, Munro R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med 1982;97:344-350.
114. Myers JP, Linnemann CC. Bacteremia due to methicillin-resistant Staphylococcus aureus. J Infect Dis 1982;145:532-536.
115. Cafferkey MT, Hone R, Keane CT. Severe staphylococeal infections treated with vancomycin. J Antimicrob Chemother 1982;9:69-74.
116. Craven DE, Kollisch N, Hsieh C., Connolly MG, McCabe WR. Vancomycin treatment of bacteremia caused by oxacillin-resistant Staphylococcus aureus: Comparison with β-lactam antibiotic treatment of bacteremia caused by oxacillin-sensitive Staphylococcus aureus. J Infect Dis 1983;147:137-143.
117. Coppens L, Hanson B, Klastersky J. Therapy of staphylococcal infections with cefamandole or vancomycin alone or with a combination of celamandole and tobramycin. Antimicrob Agents Chemothcr 1983;23:36-41.
118. Klastersky J, Coppens L, van der Auwera P, Meunier-Carpentier F. Vancomycin therapy of oxacillin-resistant Staphylococus aureus infections. J Antimicrob Chemother 1983;11:361-367.
119. French GL, Cheng AFB, Ling ML, Mo P, Donnan S. Hong Kong strains of methicillin-resistant and methicillin-sensitive Staphylococcus aureus have similar virulence. J Hosp Infect 1990;15:117-125.
120. Sheftel TG, Mader JT, Pennick JJ, Cierny G. Mcthicillin-resistant Staphylococcus aureus osteomyelitis. Clin Orthoped Related Res 1985;198:231-259.
121. Ish-Horowicz MR, McIntyre P, Nade S. Bone and joint infections caused by multiply resistant Staphylococcus aureus in a neonatal intensive care unit. Pediatr Infect Dis J 1992;11:82-87.
122. Markowitz M, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxaxole compared with Vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992;117:390-398.
123. Hartstein AI, Mulligan ME, Morthland VH, Kwok RYY. Recurrent Staphylococcus aureus bacteremia. J Clin Microbiol 1992; 30:670-674.
124. Chambers HF, Miller RT, Newman MD. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med 1988; 109 (8):619-624.
125. Jackson MA, Hicks RA. Vancomycin failure in staphylococcal endocarditis. Pediatr Infect Dis J 1987; 6(8):750-752.
126. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum Vancomycin concentrations: Reappraisal of their clinical value. Clin Infect Dis 1994;18:533-543.
127. Moellering Jr RC. Editorial: Monitoring serum vancomycin levels: climbing the mountain because it is there? Clin Infect Dis 1994;18:544-546.
128. Edwards DJ, Pancorbo S. Routine monitoring of serum vancomycin concentrations: waiting for proof of its value. Clin Pharmacol 1987; 6:652-654.
129. Rodvold RA, Zofuka H, Rotschafer JC. Routine monitoring of serum vancomycin concentrations: can waiting be justified? Clin Pharacol 1987;6:655-658.
130. Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic drug monitoring: Is it necessary? Ann Pharmacother 1993;27:594-598.
131. Schaad UB, McCracken Jr GH, Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 1980; 96:119-26.
132. Louria DB, Kaminski T, Buchman J. Vancomycin in severe staphylococcal infections. Arch Intern Med 1961; 107:225-240.
133. Venditti M, Baiocchi P, Santini C, et al. Potential of clindamycin in addition to vancomycin for the treatment of oxacillin-resistant Staphylococcus aureus septicemia persisting under vancomycin therapy. Int J Antimicrob Agents 1995;5:123-128.
134. Ackerman BH, Vannier AM. Necessity of a loading dose when using vancomycin in critically ill patients. J Antimicrob Chemother 1992;29:460-461.
135. Dutfull SB, Begg FJ. Vancomycin toxicity. What is the evidence for dose dependency. Adverse Drug React Toxicol Rev 1994;13:103-114.
136. Conil JM, Favarel H, Laguerre J, et al. Continuous administration of vancomycin in patients with severe bums. Presse Med 1994; 23:1554-8.
137. Barois A, Estournet B, Moranne JB, et al. Ventricular staphylococcal infections. Treatment with vancomycin by continuous venous infusion. Presse Med 1986;15(36):1805-8.
138. Longuet P, Vallee E, Michel M, et al. Vancomycin in meningitis caused by penicillin G resistant Streptococcus pneumoniae. Presse Med 1993;22:1818-9.
139. Wysocki M, Thomas F, Wolff MA, et al. Comparison of continuous with discontinuous intravenous infusion of vancomycin in severe MRSA infections. J Antimicrob Chemother 1995; 35:352-354.
140. Bouffet E, Fuhrmann C, Frappaz D, et al. Once daily antibiotic regimen in paediatric oncology. Arch Dis Child 1994; 70:484-7
141. Gilbert C, Meisenberg B, Vredenburgh J, et al. Sequential prophylactic oral and empiric once-daily parenteral antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J Clin Oncol 1994; 12:1005-11.
142. Cruciani M, Concia E, DiPerri G, et al. Teicoplanin in the treatment of gram-positive bacteremia and endocarditis. Curr Ther Res 1992;51:704-714.
143. Wilson APR, Grüneberg RN, Neu H. A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimicrob Agents 1994;4 (Suppl 1):S1-S30.
144. Stille W, Sietzen W, Dieterich H-A, Fell JJ. Clinical efficacy and safety of teicoplanin. J Antimicrob Chemother 1988;21 (suppl A):69-79.
145. Gilbert DN, Wood CA, Kimbrough RC, and The Infectious Disease Consortium of Oregon. Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. Antimicrob Agents Chemother 1991;35:79-87.
146. Calain P, Krause K-U, Vaudaux P, et al. Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J Infect Dis 1987;155:187-191.
147. Galanakis N, Giamarellou U, Vlachogiannis N, Dendrinos C, Daikos GK. Poor efficacy of teicoplanin in treatment of deep-seated staphylococcal infection. Eur J Clin Microbiol Infect Dis 1988;7:130-134.
148. Glupczinski Y, Lagast H, Van der Auwera et al. Clinical evaluation of teicoplanin for therapy of severe infections caused by gram positive bacteria. Antimicrob Agents Chemother 1986;29:52-57.
149. Lang E, Foldes M, Marghescu S. Teicoplanin in der Behandlung von Haut- und Weichteilinfektionen: Ergebnisse einer Multicenter-Studie. Fortschritte der antimikrobiellen und antineoplastischen. Chemotherapy 1992;11:625-633.
150. Fortun J, Perez-Molina JA, Anon MT, Martinez-Beltran J, Loza E, Guerrero A. Right-sided endocarditis caused by Staphylococcus aureus in drug abusers. Antimicrob Agents Chemother 1995;39:525-8.
151. Greenberg RN. Treatment of bone, joint, and vascular-access-associated Gram-positive bacterial infections with teicoplanin. Antimicrob Agents Chemother 1990;34:2392-2397.
152. Rybak MJ, Cappelletty DM, Kang SE, Levine DP, Levison ME. Pharmacodynamic (PD) evaluation of teicoplanin (T) versus vancomycin (V) in the treatment of Gram-positive bacteremia (B) and endocarditis (E). Abstract A36. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana. September 16, 1996.
153. Marone P, Concia E, Andreoni M, Suter F, Cruciani M. Treatment of bone and soft tissue infections with teicoplanin. J Antimicrob Chemother 1990;25:435-9.
154. Graninger W, Wenisch C, Wiesinger E, Menschik M, Karimi J, Presterl E. Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis. Eur J Clin Microbiol Infect Dis 1995;14:643-7.
155. Weinberg WG. Safety and efficacy of teicoplanin for bone and joint infections: results of a community-based trial. Southern Med J 1993;86:891-7.
156. Schmit JL. Efficacy of teicoplanin for enterococcal infections. 63 cases and review. Clin Infect Dis 1992;15:302-306.
157. Martine P, Venditti M, Micozzi A, et al. Teicoplanin in the treatment of gram-positive bacterial endocarditis. Antimicrob Agents Chemother 1989;33:1329-1334.
158. Leport C, Perronne C, Massip P, et al. Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients. Antimicrob Agents Chemother 1989;33(6):871-6.
159. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. Clinical pharmacokinetic concepts. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 1995;28:143-160.
160. Cremieux AC, Carbon C. Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experi mental endocarditis. Antimicrob Agents Chemother 1992;36:2069-2074.
161. Wilson APR, Gruneberg RN, Neu HC. Dosage recommendations for teicoplanin. J Antimicrob Chemother 1993;32:792-796.
162. Lerner S. Perspectives on teicoplanin: discussion. Scand J Infect Dis 1991;22(Suppl.):61-67.
163. Rybak MJ, Lerner SA, Levine DP, et al. Teicoplanin pharmacokinctics in intravenous drug abusers being treated for bacterial endocarditis. Antimicrob Agents Chemother 1991;35:696-700.
164. Cremieux AC, Maxiere B, Vallois JM, et al. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J Infect Dis 1989;159:938-944.
165. Lin SC. Sample size for therapeutic equivalence based on confidence interval. Drug Information J 1995;29:45-50.
166. Makuch A, Simon R. Sample size requirements for evaluating a conservative therapy. Cancer Treat Rep 1978;7:1037-1040.
167. Marchant CD, Carlin SA, Johnson CE, Shurin PA. Measuring the comparative efficacy of antibacterial agents for acute otitis media: The "Pollyanna phenomenon." J Pediatr 1992;120:72-77.
168. Wood MJ. Review: The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996;37:209-222.
169. Egger M, Smith GD, Song F, Sheldon TA. Review: Making sense of meta-analysis. Pharmacoepidemiol Drug Safety 1992;2:65-72.
170. Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TG. Special Article: Meta-analyses of of randomized controlled trials. N Engl J Med 1987;316:450-455.
171. Cobo J, Fortun J. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996;38:1113-1114.
172. Chow AW, Jewesson PJ, Kureishi A, Phillips GL. Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients. Eur J Haematol 1993;51:suppl. 54:18-24.
173. Rolston KVI, Nguyen H, Amos G, et al. A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of Gram-positive bacteremia in patients with cancer. J Infect Dis 1994;169:350-355.
174. Hedstrom SA, Nordic Teicoplanin Study Group. Teicoplanin vs vancomycin in severe gram-positive infection: a multicentre Scandinavian trial. Abstract 760. In: Abstracts of the Seventh European Congress of Clinical Microbiology and Infectious Diseases, Vienna Austria, 1995.
175. Schlech WF, and the Teicoplanin Study Group of North America. A randomised, blinded, comparative study of teicoplanin vs vancomycin in the treatment of vascular-access associated bacteremia caused by Gram-positive bacteria. In Programs and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Anaheim, California, 1992. October 11, 1992.
176. Van Laethem Y, Hermans P, De Wit S, Goosens H, Clumeck N. Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results. J Antimicrob Chemother 1988;21 (Suppl. A):81-87.
177. Liu C-Y, Lee W-S, Fung C-P, et al. Comparative study of teicoplanin versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Drug Invest 1996;12:80-87.
178. Charbonneau P, Harding I, Garraud JJ, et al. Teicoplanin: a safe and easily administered alternative to vancomycin for Gram-positive infections in
179. Hung C-C, Chang S-C, Chen Y-C, Hsieh W-C. A randomised trial of teicoplanin versus vancomycin for the treatment of serious gram-positive infections. J Infect Dis Soc ROC 1995;6:97-103.
180. Neville LO, Brumfitt W, Hamilton-Miller JMT, Harding I. Teicoplanin vs. vancomycin for the treatment of serious infections: a randomised trial. Int J Antimicrob Agents 1995;5:187-193.
181. Van der Auwera P, Aoun M, Meunier F. Randomized study of vancomycin versus teicoplanin for the treatment of Gram-positive bacterial infections in immunocompromised hosts. Antimicrob Agents Chemother 1991;55;451-457.
182. Gelfand MS, Simmons BP, Threlkeld MG, et al. Randomized double-blind study of teicoplanin and vancomycin in gram-positive bacteremia (GPB) and endocarditis (GPE). Clin Res 1991;39:809A.
183. Menichetti F, Martino P, Bucaneve G, et al. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Antimicrob Agents Chemother 1994;38:2041-2046.
184. Figuera A, Tomas JF, Hernandez ML, et al. Imipenem combined with teicoplanin or vanocmycin in the initial empiric therapy of fevbrile neutropenia. Analysis of the primary response and of an overall sequential strategy in 126 episodes. Rev Clin Esp 1966;196:512-522.
185. Cony-Makhoul P, Brossard C, Marit G, et al. A prospective study comparing vanocmycin and teicoplanin as second-line empiric therapy for infection in neutropenic patients. Br J Haematol. 1990;76(Suppl 2):35-40.
186. Smith SR, Cheesbrough J, Spearing K, Davies JM. Randomized prospective study comparing vanocmycin with teicoplanin in the treatment of infections associated with Hickman catheters. Antimicrob Agents Chemother 1989;33:1193-1197.
187. Ktireishi A, Jewesson PJ, Rubinger M, et al. Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin - effect on cyclosporin A-associated nephrotoxicity. Antimicrob Agents Chemother 1991;35:2246-2252.
188. Al-Wali W, Baillod RA, Brumfitt W, Hamilton-Miller JMT. Teicoplanin in the treatment of peritonitis in patients receiving continuous ambulatory peritoneal dialysis: a comparative trial against vancomycin. Int J Antimicrob Agents 1992;1:S1-S6.
189. Al-Wali W, Baillod RA, Brumfitt W, Hamilton Miller JMT. Intraperitoneal teicoplanin in CAPD peritonitis. Perit Dial Int 1990; 10(1): 107-8.
190. '190 Schinella D, de Bas H, Franceschin A. Intraperitoneal teicoplanin in CAPD peritonitis. Perit Dial Int 1989; 8: 145.
191. Meunier F, van der Auwera P, Aoun M, Piccart M, Seulier JP. Therapy of infections related to intraperitoneal catheters in patients with ovarian cancer. Stand J Infect Dis 1990;72(Suppl):26-8.
192. Williams AH. Comparative safety of teicoplanin and other gram-positive agents. In Gruneberg, RN, ed., Teicoplanin: Further European Experience. London: Royal Society of Medicine. 1990: 75-79.
193. Terol MJ, Sierra J, Gatell JM, Rozman C. Thrombocytopenia due to use of teicoplanin. Clin Infect Dis 1993; 17: 927.
194. Pachon J, Prados D, Palomino J, et al. Efficacy and safety of teicoplanin in infections caused by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1996;37:198-200.
195. Walker RW, Heaton A. Thrombocytopenia due to vancomycin. Lancet 1985;1:932.
196. Zenon GJ, Cadle RM, Hamill RJ. Vancomycin induced thrombocytopenia. Arch Intern Med 1991;151:995-996.
197. Chow AW, Azar RM. Glycopeptides and nephrotoxicity. Intensive Care Med 1994;2(Suppl):S23-S29.
198. Appel GB, Neu HC. The nephrotoxicity of antimicrobial agents (second of three parts). N Engl J Med 1977; 296: 722-728.
199. Waisbren BA, Kleinerman L, Skemp I, Bratcher G. Comparative clinical effectiveness and toxicity of vanocmycin, ristocetin, and kanamycin. Arch Int Med 1960;106:179-193.
200. Rybak MJ., Albrecht LM, Boike SC, Chandresekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990;25:679-687.
201. Mellor JA, Kingdom J, Cafferkey M, Keane CT. Vancomycin toxicity: a prospective study. J Antimicrob Chemother 1985;15:773-780.
202. Eng RHK., Wynn L, Smith SM, Tecson-Tumang F. Effect of intravenous vancomycin on renal function. Chemotherapy 1989;35:320-325.
203. Downs NJ, Neihart RE, Dolezal JM, Hodges GR. Mild nephrotoxicity associated with vancomycin use. Arch Intern Med 1989;149:I777-1781.
204. Cimino MA, Rotstein C, Slaughter RL, Emrich LJ. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med 1987;83:1091-1097.
205. Farber BF, Moellering RC. Retrospective study of the toxicity of preparations of vancomycin from 1974 - 1981. Antimicrob. Agents Chemother 1983;23:138-141.
206. Davey PG, Williams AH. A review of the safety profile of teicoplanin. J Antimicrob Chemother 1991;27(Suppl B) 69-73.
207. Sahai J, Healy DP, Shelton MJ, Miller JS, Ruberg SJ, Polk R. Comparison of vancomycin and teicoplanin-induced histamine release and "red man syndrome". Antimicrob Agents Chemother 1990;34:765-769.
208. Dubettier S, Boibieux A, Lagable M, et al. Red man syndrome with teicoplanin. Rev Infect Dis 1991; 13: 770.
209. Grek V, Andrien F, Collignon J, Fillet G. Allergic cross-reaction of teicoplanin and vancomycin. J Antimicrob Chemother 1991;28:476-477.
210. Levy JH, Kettlekamp N, Goertz P, Hermens J, Hirshman CA. Histamine release by vancomycin: a mechanism for hypotension in man. Anesthesiology 1987;67:122-125.
211. Polk RL, Healy DP, Schwartz LB, Rock DT, Garson ML, Roller K. Vancomycin and the red-man syndrome: pharmacodynamics of histamine release. J Infect Dis 1988;157:502-507.
212. Mealy DP, Sahai JV, Fuller SM, Polk RE. Vancomycin-induced histamine release and "red man syndrome": comparison of 1- and 2-hour infusions. Antimicroh Agents Chemother 1990;34(4):550-554.
213. Sahai J, Healy DP, Garris R, Berry A, Polk RE. Influence of antihistamine pretreatment on vancomycin-induced red-man syndrome. J Infect Dis 1989;160(5):867-881.
214. Wallace MR, Mascola JR, Oldfield EC. Red man syndrome: incidence, etiology and prophylaxis. J Infect Dis 1991;164:1180-1185.
215. Schlemmer B, Falkman H, Boudadja A, Jacob L, Le Gall JR. Teicoplanin for patients allergic to vancomycin. N Engl J Med 1988;318:1127-1128.
216. Wood G, Whitby M. Teicoplanin in patients who are allergic to vancomycin (letter). Med J Australia 1989; 150: 668.
217. Smith SR, Cheesbrough JS, Makris M, Davies J.M. Teicoplanin administration in patients experiencing reactions to vancomycin. J Antimicrob Chemother 1989;23:810-812.
218. McElrath JJ, Goldberg D, Neu HC. Allergic cross-reactivity of teicoplanin and vancomycin (letter). Lancet 1986;1:47.
219. Lewis EW, Gibson CB, Heilman CJ, et al. Teicoplanin administration in patients with vancomycin hypersensitivity. Abstract 1672. In Programs and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim California. October 11, 1992.
220. Del Favero A, Patoia L, Rosina R. Pharmacokinetics and tolerability of teicoplanin in healthy volunteers after single increasing doses. Antimicrob Agents Chemother 1991;35:2551-7.
221. Charbonneau P, Harding I, Garaud JJ, et al. Teicoplanin: A well-tolerated and easily administered alternative to vancomycin for Gram-positive infections in intensive care patients. Intensive Care Med 1994;20(Suppl):S35-S42.
222. De Lalla F, Nicolin R, Rinaldi E, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 1992;36:2192-2196.
223. Wenisch C, Parschalk B, Hassenhundl M, Hirschl AM, Graninger W. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996;22:813-818.